Progenics Pharma initiates clinical trial of 1095 radiotherapy
Category: #health  By Pankaj Singh  Date: 2019-06-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Progenics Pharma initiates clinical trial of 1095 radiotherapy

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, has recently announced that its first patient has been dosed for treatment of Metastatic Prostate cancer, in a phase 2 clinical study of 1095 radiotherapy. The clinical study evaluated I-131 1095 radiotherapy in combination with enzalutamide to treat mCRPC (metastatic castration resistant prostate cancer), reports source.

As per credible sources, a placebo controlled phase 2 clinical study is evaluating the efficiency of 1095 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer, who are new to chemotherapy, PSMA-avid & progressed on abiraterone. 18F-DCFPyL, the company’s patented imaging agent to visualize cancer, will be used to determine PSMA-avidity.

Nuclear Medicine Physician at LHSC, Scientist at Lawson Health Research Institute & Joseph’s Health Care London, Canada, Dr. David Laidley, was reported to say that 1095 radiotherapy is a potential treatment option for prostate cancer as it may overcome resistance developed to new androgen axis drugs, such as enzalutamide and abiraterone. Th resistance of anti-androgen drugs in the pre-chemotherapy patients is growing, which further reinforces need to advance new targeted therapies.

Asha Das, M.D., Chief Medical Officer, Progenics Pharmaceuticals, Inc., was reportedly quoted saying that phase 2 clinical study of 1095 radiotherapy to treat metastatic patients at an earlier stage utilizing a differentiated, PSMA-targeted approach, is a significant milestone.

Data from the study demonstrated 1095’s potential to reduce PSA & bone pain in heavily pretreated prostate cancer patients and was well tolerated. The preclinical data suggest combination of radiotherapy & enzalutamide is potentially a more effective treatment model for patients with mCRPC., Das added.

As per sources close to the matter, the study is expected to enroll 120 patients at 25 sites in Canada and the U.S. The study’s main endpoint is PSA (prostate specific antigen) response rate, according to PCWG3 (Cancer Clinical Trials Working Group 3). The criteria include a confirmed 50 per cent or greater decline from baseline. The secondary endpoint to evaluate response is based on RECIST (Response Evaluation Criteria in Solid Tumors), for soft tissue, PFS (progression free survival) and overall survival. Patients will be followed for 1 year after their first treatment of all efficacy endpoints.

Source credits: https://progenicsgc.gcs-web.com/news-releases/news-release-details/progenics-pharmaceuticals-doses-first-patient-phase-2-clinical

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
By Pankaj Singh

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company ha...

VMware plans to acquire Nyansa to expand its SW-WAN portfolio
VMware plans to acquire Nyansa to expand its SW-WAN portfolio
By Pankaj Singh

  The deal for the acquisition will close in the first quarter of the FY2021 The terms of the deal have not been disclosed by the company yet VMware, a leading provider of virtualization and cloud computing software and services, recently ...

Rogers Communications launches 5G network services across Canada
Rogers Communications launches 5G network services across Canada
By Pankaj Singh

  The network will first be implemented in Toronto, Vancouver, Montreal and Ottawa Rogers has collaborated with Ericsson to provide the required technology to develop the network Rogers Communications – a Toronto based telecommunicat...